Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
Platinum-based chemotherapy rechallenge is reasonable for patients with platinum-sensitive disease, using the traditional PFI cutoff of 6 months, even when the PFI is obtained with a maintenance PARP inhibitor.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Takehiro Nakao (ORCID: https://orcid.org/0009-0008-4421-0997)
- Hiroshi Tanabe (ORCID: https://orcid.org/0000-0002-1301-719X)
- Toru Mukohara (ORCID: https://orcid.org/0000-0002-8573-418X)
- Masashi Wakabayashi (ORCID: https://orcid.org/0009-0001-6368-5671)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
Institutions
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1016/j.gore.2024.101482
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28